GlassScriptPhysician profile
Katie Hanson
NPI 1114201613
$811.42
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $58.49 · 2022: $57.41 · 2023: $86.84 · 2024: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $696.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $695.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $200.48 | 2024 | Spravato |
| Zimmer Biomet Holdings, INC. | $135.96 | 2024 | Dvr Anatomic Kickstand, A.L.P.S. |
| Abbvie INC. | $106.29 | 2024 | |
| Depuy Synthes Sales INC. | $97.42 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $70.41 | 2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Stryker Corporation | $65.44 | 2023 | |
| Lundbeck LLC | $28.26 | 2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.95 | 2024 | Caplyta |
| Orthofix Medical, INC. | $21.40 | 2023 | Physio-Stim |
| Noven Therapeutics, LLC | $20.38 | 2024 | Xelstrym |
| Teva Pharmaceuticals USA, INC. | $18.95 | 2024 | Uzedy |
| Mvp Orthopedics INC | $18.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Hanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.